Cellectar BioSciences, Inc. Stock

$7.90

7.05% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US15117F3029

Symbol

CLRB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cellectar BioSciences, Inc. Stock price

$7.90

-382.10 97.97% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.52 7.05%

ISIN

US15117F3029

Symbol

CLRB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$14.3m

Enterprise Value

$410.0k

Net debt

$-13.9m

Cash

$13.9m

Shares outstanding

46.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

37.78

Financial Health

Equity Ratio

61.54%

Return on Equity

-284.38%

ROCE

-460.85%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-45.9m | -

EBIT

$-46.2m

Net Income

$-24.5m | $-27.4m

Free Cash Flow

$-43.6m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-9.31% | -

EBIT

-9.30%

Net Income

56.21% | 38.49%

Free Cash Flow

-10.55%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.53

FCF per Share

$-0.95

Short interest

4.49%

Employees

11.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Cellectar BioSciences, Inc. Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Cellectar BioSciences, Inc. forecast:

7x Buy

70%

3x Hold

30%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Cellectar BioSciences, Inc. forecast:

Buy

70%

Hold

30%

Analyst Estimates with Stock Price Targets

Financial data from Cellectar BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	24 24	74% 74% -
- Research and Development Expense	22 22	22% 22% -
EBITDA	-46 -46	9% 9% -
- Depreciation and Amortization	0.26 0.26	8% 8% -
EBIT (Operating Income) EBIT	-46 -46	9% 9% -
Net Profit	-25 -25	56% 56% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cellectar BioSciences, Inc. Stock News

Neutral

GlobeNewsWire

●

2 days ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the...

Neutral

GlobeNewsWire

●

4 days ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, to...

Neutral

GlobeNewsWire

●

10 days ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “Reverse Stock Split”) of the company's common stock, par value $0.00001, which will become effective at 12:01 a.m...

More Cellectar BioSciences, Inc. News

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Head office	United States
CEO	James Caruso
Employees	11
Founded	1996
Website	www.cellectar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now